Review Article | Published:

Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases

Nature Reviews Drug Discovery volume 16, pages 5370 (2017) | Download Citation

Abstract

Granulocyte–macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF; also known as CSF1), granulocyte colony-stimulating factor (G-CSF) and interleukin-3 (IL-3) can each play a part in the host response to injury and infection, and there is burgeoning interest in targeting these CSFs in inflammatory and autoimmune disorders, as well as in cancer. For success in clinical medicine, therapeutic targeting will need to be delineated from current strategies. The individual CSFs have unique biological roles, suggesting that they could be used to target specific conditions. This Review compares the CSFs, with a focus on how they could be targeted, discusses the relevant clinical trial data and summarizes the potential clinical applications of targeting each CSF. Importantly, we discuss the novelty of CSF biology and attempt to clarify some of the surrounding misconceptions and issues that can affect therapeutic decisions.

Key points

  • Colony-stimulating factors (CSFs) are pleiotropic, but each has its own unique biological role.

  • All CSFs control myeloid cell numbers, but each has a level of specificity in regard to its target cells and effects.

  • Preclinical and/or clinical data suggest that targeting granulocyte–macrophage CSF (GM-CSF), CSF1, granulocyte CSF (G-CSF) or IL-3 could be useful in the treatment of numerous autoimmune and/or inflammatory pathologies, including rheumatoid arthritis and multiple sclerosis. Further investigation of the potential of targeting CSFs in other pathologies is warranted.

  • CSF targeting, as well as associated patient stratification, should be based on the specific CSF biology.

  • There is not necessarily an inverse relationship between the effects of CSF blockade and administration of the protein itself on a particular pathology.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & The nature and action of granulocyte-macrophage colony stimulating factors. Blood 56, 947–958 (1980).

  2. 2.

    Hematopoietic cytokines. Blood 111, 485–491 (2008).

  3. 3.

    Colony-stimulating factors in inflammation and autoimmunity. Nat. Rev. Immunol. 8, 533–544 (2008).

  4. 4.

    , , & Stimulation of macrophage plasminogen activator activity by colony-stimulating factors. J. Cell. Physiol. 103, 435–445 (1980).

  5. 5.

    et al. Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus. Clin. Exp. Immunol. 183, 258–270 (2016).

  6. 6.

    et al. Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma. BMJ Open 6, e007709 (2016).

  7. 7.

    et al. Results from a phase IIa parallel group study of JNJ-40346527, an oral CSF-1R inhibitor, in patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy. J. Rheumatol. 42, 1752–1760 (2015).

  8. 8.

    et al. Long-term safety and efficacy of Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor-α (GM-CSFR-α) monoclonal antibody, in patients with rheumatoid arthritis (RA). Arthritis Rheumatol. 67 (Suppl. 10), abstr. 3111 (2015). This recent long-term (74-week) OLE study reports a sustained benefit of an anti-GM-CSFR mAb in individuals with RA (n >300) without safety issues.

  9. 9.

    & Colony stimulating factors and myeloid cell biology in health and disease. Trends Immunol. 34, 81–89 (2013).

  10. 10.

    et al. The βc receptor family — structural insights and their functional implications. Cytokine 74, 247–258 (2015).

  11. 11.

    GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential. Expert Rev. Clin. Immunol. 11, 457–465 (2015).

  12. 12.

    & Targeting GM-CSF in inflammatory diseases. Nat. Rev. Rheumatol. 12, 37–48 (2016).

  13. 13.

    et al. GM-CSF increases cross-presentation and CD103 expression by mouse CD8 spleen dendritic cells. Eur. J. Immunol. 41, 2585–2595 (2011).

  14. 14.

    , & Systematic cytokine receptor profiling reveals GM-CSF as a novel TLR-independent activator of human plasmacytoid predendritic cells. Blood 115, 5037–5040 (2010).

  15. 15.

    et al. Cutting edge: granulocyte-macrophage colony-stimulating factor is the major CD8+ T cell-derived licensing factor for dendritic cell activation. J. Immunol. 184, 4625–4629 (2010).

  16. 16.

    Rheumatoid arthritis: opposing actions of haemopoietic growth factors and slow-acting anti-rheumatic drugs. Lancet 342, 536–539 (1993). This original 'CSF network' hypothesis linked the pro-inflammatory actions of the CSFs with those of other pro-inflammatory cytokines (IL-1 and TNF) in a positive loop to help to explain the chronicity of inflammatory lesions.

  17. 17.

    et al. RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 12, 560–567 (2011).

  18. 18.

    et al. GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J. Exp. Med. 205, 2281–2294 (2008).

  19. 19.

    et al. The cytokine GM-CSF drives the inflammatory signature of CCR2+ monocytes and licenses autoimmunity. Immunity 43, 502–514 (2015).

  20. 20.

    , , , & Breaking the vicious cycle between breast cancer cells and tumor-associated macrophages. Oncoimmunology 3, e953418 (2014).

  21. 21.

    et al. Pathogenic IL-23 signaling is required to initiate GM-CSF-driven autoimmune myocarditis in mice. Eur. J. Immunol. 46, 582–592 (2016).

  22. 22.

    et al. The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell 134, 496–507 (2008). This paper described the crystal structure of the human GM-CSFR as an unusual dodecamer formed from an association of two hexamers containing two molecules each of the ligand, the receptor α-chain and the receptor β-chain).

  23. 23.

    et al. Conformational changes in the GM-CSF receptor suggest a molecular mechanism for affinity conversion and receptor signaling. Structure 24, 1271–1281 (2016).

  24. 24.

    , & Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. Blood 119, 3383–3393 (2012).

  25. 25.

    et al. Analysis of the transcriptional networks underpinning the activation of murine macrophages by inflammatory mediators. J. Leukoc. Biol. 96, 167–183 (2014).

  26. 26.

    , , & Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice. Ann. Rheum. Dis. 56, 364–368 (1997).

  27. 27.

    et al. A GM-CSF/IL-33 pathway facilitates allergic airway responses to sub-threshold house dust mite exposure. PLoS ONE 9, e88714 (2014).

  28. 28.

    et al. Transgenic expression of GM-CSF in T cells causes disseminated histiocytosis. Am. J. Pathol. 184, 184–199 (2014).

  29. 29.

    , & GM-CSF: a role in immune and inflammatory reactions in the intestine. Expert Rev. Gastroenterol. Hepatol. 4, 723–731 (2010).

  30. 30.

    et al. GM-CSF: an immune modulatory cytokine that can suppress autoimmunity. Cytokine 75, 261–271 (2015).

  31. 31.

    et al. Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. J. Immunol. 161, 3639–3644 (1998). This paper was the first evidence for a pro-inflammatory role of endogenous GM-CSF by showing that GM-CSF-deficient mice were protected from collagen-induced arthritis.

  32. 32.

    , , , & Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res. 3, 293–298 (2001). This paper was the first to show that a mAb against GM-CSF can suppress an inflammatory disease. It demonstrated that therapeutic administration of a mAb against GM-CSF suppressed collagen-induced arthritis in the effector phase of disease.

  33. 33.

    et al. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J. Exp. Med. 194, 873–882 (2001).

  34. 34.

    et al. GM-CSF and uPA are required for Porphyromonas gingivalis-induced alveolar bone loss in a mouse periodontitis model. Immunol. Cell Biol. 93, 705–715 (2015).

  35. 35.

    et al. Granulocyte macrophage colony-stimulating factor is required for aortic dissection/intramural haematoma. Nat. Commun. 6, 6994 (2015).

  36. 36.

    et al. GM-CSF but not IL-17 is critical for the development of severe interstitial lung disease in SKG mice. J. Immunol. 193, 849–859 (2014).

  37. 37.

    et al. Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis. Arthritis Res. Ther. 17, 163 (2015).

  38. 38.

    , & The role of granulocyte-macrophage colony-stimulating factor in acute intestinal inflammation. Cell Res. 18, 1220–1229 (2008).

  39. 39.

    et al. CD45 regulates GM-CSF, retinoic acid and T-cell homing in intestinal inflammation. Mucosal Immunol. 9, 1514–1527 (2016).

  40. 40.

    , , , & Granulocyte-macrophage colony-stimulating factor (GM-CSF): a chemoattractive agent for murine leukocytes in vivo. J. Leukoc. Biol. 89, 945–953 (2011).

  41. 41.

    , , & Dysregulated hematopoietic stem and progenitor cell activity promotes interleukin-23-driven chronic intestinal inflammation. Immunity 37, 1116–1129 (2012).

  42. 42.

    et al. Granulocyte macrophage colony-stimulating factor-activated eosinophils promote interleukin-23 driven chronic colitis. Immunity 43, 187–199 (2015).

  43. 43.

    et al. Unique and redundant functions of NKp46+ ILC3s in models of intestinal inflammation. J. Exp. Med. 212, 1869–1882 (2015).

  44. 44.

    et al. ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation. eLife 5, e10066 (2016).

  45. 45.

    , , & Development and functional specialization of CD103+ dendritic cells. Immunol. Rev. 234, 268–281 (2010).

  46. 46.

    , & GM-CSF-dependent, CD103+ dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunization. J. Exp. Med. 207, 953–961 (2010).

  47. 47.

    et al. GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells. Immunity 36, 1031–1046 (2012).

  48. 48.

    et al. Batf3-dependent CD11blow/− peripheral dendritic cells are GM-CSF-independent and are not required for Th cell priming after subcutaneous immunization. PLoS ONE 6, e25660 (2011).

  49. 49.

    et al. The closely related CD103+ dendritic cells (DCs) and lymphoid-resident CD8+ DCs differ in their inflammatory functions. PLoS ONE 9, e91126 (2014).

  50. 50.

    et al. Differentiation of inflammatory dendritic cells is mediated by NF-κB1-dependent GM-CSF production in CD4 T cells. J. Immunol. 186, 5468–5477 (2011).

  51. 51.

    et al. GM-CSF-responsive monocyte-derived dendritic cells are pivotal in Th17 pathogenesis. J. Immunol. 192, 2202–2209 (2014).

  52. 52.

    et al. Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes. Nat. Immunol. 7, 663–671 (2006).

  53. 53.

    et al. Specific contributions of CSF-1 and GM-CSF to the dynamics of the mononuclear phagocyte system. J. Immunol. 195, 134–144 (2015).

  54. 54.

    et al. GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c+MHCII+ macrophages and dendritic cells. Immunity 42, 1197–1211 (2015).

  55. 55.

    et al. Granulocyte macrophage colony-stimulating factor induces CCL17 production via IRF4 to mediate inflammation. J. Clin. Invest. 126, 3453–3466 (2016).

  56. 56.

    & The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. Arthritis Rheum. 60, 1210–1221 (2009).

  57. 57.

    et al. Macrophages from the synovium of active rheumatoid arthritis exhibit an activin A-dependent pro-inflammatory profile. J. Pathol. 235, 515–526 (2015).

  58. 58.

    , & Regulation of spontaneous eosinophil apoptosis— a neglected area of importance. J. Cell Death 7, 1–9 (2014).

  59. 59.

    et al. GM-CSF enhances macrophage glycolytic activity in vitro and improves detection of inflammation in vivo. J. Nucl. Med. 57, 1428–1435 (2016).

  60. 60.

    , & Identification of a non-growth factor role for GM-CSF in advanced atherosclerosis: promotion of macrophage apoptosis and plaque necrosis through IL-23 signaling. Circ. Res. 116, e13–e24 (2015).

  61. 61.

    et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat. Immunol. 12, 231–238 (2011).

  62. 62.

    , , & GM-CSF and M-CSF (CSF-1)-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities — implications for CSF blockade in inflammation. J. Immunol. 178, 5245–5252 (2007).

  63. 63.

    et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc. Natl Acad. Sci. USA 101, 4560–4565 (2004).

  64. 64.

    et al. Interleukin-1α controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33. J. Exp. Med. 209, 1505–1517 (2012).

  65. 65.

    et al. Intranasal exposure of mice to house dust mite elicits allergic airway inflammation via a GM-CSF-mediated mechanism. J. Immunol. 173, 6384–6392 (2004).

  66. 66.

    et al. Distinct roles of CSF family cytokines in macrophage infiltration and activation in glioma progression and injury response. J. Pathol. 230, 310–321 (2013).

  67. 67.

    et al. GM-CSF produced by nonhematopoietic cells is required for early epithelial cell proliferation and repair of injured colonic mucosa. J. Immunol. 190, 1702–1713 (2013).

  68. 68.

    et al. GM-CSF promotes macrophage alternative activation after renal ischemia/reperfusion injury. J. Am. Soc. Nephrol. 26, 1334–1345 (2015).

  69. 69.

    , , & Critical role of the GM-CSF signaling pathway in macrophage pro-repair activities. Pathobiology 81, 183–189 (2014).

  70. 70.

    , , , & GM-CSF- and M-CSF-dependent macrophage phenotypes display differential dependence on type I interferon signaling. J. Leukoc. Biol. 86, 411–421 (2009).

  71. 71.

    et al. Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models. J. Immunol. 188, 5752–5765 (2012).

  72. 72.

    et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41, 14–20 (2014).

  73. 73.

    et al. The encephalitogenicity of TH17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat. Immunol. 12, 568–575 (2011).

  74. 74.

    et al. STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation. Cell Res. 24, 1387–1402 (2014).

  75. 75.

    et al. IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells. Sci. Transl. Med. 6, 241ra80 (2014).

  76. 76.

    et al. Th cell diversity in experimental autoimmune encephalomyelitis and multiple sclerosis. J. Immunol. 195, 2552–2559 (2015).

  77. 77.

    , & IL-12-polarized Th1 cells produce GM-CSF and induce EAE independent of IL-23. Eur. J. Immunol. 45, 2780–2786 (2015).

  78. 78.

    et al. Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis. Sci. Transl. Med. 7, 287ra74 (2015).

  79. 79.

    et al. GM-CSF promotes migration of human monocytes across the blood brain barrier. Eur. J. Immunol. 45, 1808–1819 (2015).

  80. 80.

    Colony stimulating factors, cytokines and monocyte-macrophages — some controversies. Immunol. Today 14, 18–24 (1993).

  81. 81.

    et al. T cell expression of granulocyte-macrophage colony-stimulating factor in juvenile arthritis is contingent upon Th17 plasticity. Arthritis Rheumatol. 66, 1955–1960 (2014).

  82. 82.

    et al. Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis. Ann. Rheum. Dis. 75, 899–907 (2015).

  83. 83.

    et al. Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis. Ann. Rheum. Dis. 74, 1924–1930 (2015).

  84. 84.

    et al. Innate response activator B cells protect against microbial sepsis. Science 335, 597–601 (2012).

  85. 85.

    et al. Pleural innate response activator B cells protect against pneumonia via a GM-CSF-IgM axis. J. Exp. Med. 211, 1243–1256 (2014).

  86. 86.

    et al. Innate response activator B cells aggravate atherosclerosis by stimulating T helper-1 adaptive immunity. Circulation 129, 1677–1687 (2014).

  87. 87.

    et al. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci. Transl. Med. 7, 310ra166 (2015).

  88. 88.

    et al. Innate lymphoid cells integrate stromal and immunological signals to enhance antibody production by splenic marginal zone B cells. Nat. Immunol. 15, 354–364 (2014).

  89. 89.

    , , , & Granulocyte-macrophage colony stimulating factor exerts protective and immunomodulatory effects in cortical trauma. J. Neuroimmunol. 278, 162–173 (2015).

  90. 90.

    et al. A neuroprotective function for the hematopoietic protein granulocyte-macrophage colony stimulating factor (GM-CSF). J. Cereb. Blood Flow Metab. 28, 29–43 (2008).

  91. 91.

    et al. Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain. Nat. Med. 15, 802–807 (2009). This paper demonstrated that GM-CSF has a role in bone cancer pain and can itself induce pain.

  92. 92.

    et al. Transcriptional mechanisms underlying sensitization of peripheral sensory neurons by granulocyte-/granulocyte-macrophage colony stimulating factors. Mol. Pain 9, 48 (2013).

  93. 93.

    , , , & Distribution of granulocyte-monocyte colony-stimulating factor and its receptor α-subunit in the adult human brain with specific reference to Alzheimer's disease. J. Neural Transm. (Vienna) 119, 1389–1406 (2012).

  94. 94.

    et al. Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development. Arthritis Res. Ther. 14, R199 (2012).

  95. 95.

    et al. Granulocyte-macrophage colony-stimulating factor is a key mediator in inflammatory and arthritic pain. Ann. Rheum. Dis. 72, 265–270 (2013).

  96. 96.

    et al. GM-CSF action in the CNS decreases food intake and body weight. J. Clin. Invest. 115, 3035–3044 (2005).

  97. 97.

    , , & GM-CSF is not essential for optimal fertility or for weight control. Cytokine 57, 30–31 (2012).

  98. 98.

    et al. The role of GM-CSF in adipose tissue inflammation. Am. J. Physiol. Endocrinol. Metab. 295, E1038–E1046 (2008).

  99. 99.

    , , , & Fertility impairment in granulocyte-macrophage colony-stimulating factor-deficient mice. Biol. Reprod. 60, 251–261 (1999).

  100. 100.

    et al. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann. Rheum. Dis. 70, 1542–1549 (2011).

  101. 101.

    et al. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann. Rheum. Dis. 72, 1445–1452 (2013).

  102. 102.

    et al. Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study. Mod. Rheumatol. 25, 21–30 (2015).

  103. 103.

    et al. Efficacy and safety of mavrilimumab, a fully human GM-CSFR-α monoclonal antibody in patients with rheumatoid arthritis: primary results from the earth explorer 1 study. Ann. Rheum. Dis. 74 (Suppl 2), 78 (2015).

  104. 104.

    et al. Rapid onset of clinical benefit in patients with RA treated with mavrilimumab, a fully human monoclonal antibody targeting GM-CSFR-α: subanalysis of the phase IIb earth explorer 1 study. Ann. Rheum. Dis. 74 (Suppl 2), 723 (2015).

  105. 105.

    et al. Patient-reported outcomes (PROS) during treatment with mavrilimumab, a fully human monoclonal antibody targeting GM-CSFR-α, in the phase IIb earth explorer 1 study. Ann. Rheum. Dis. 74 (Suppl 2), 483 (2015).

  106. 106.

    et al. Analysis of patient reported outcomes during treatment with mavrilimumab, a human monoclonal antibody targeting GM-CSFRa, in the randomized phase IIb earth explorer 1 study. ACR abstr. 1485 (2014).

  107. 107.

    et al. Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis. Nat. Commun. 6, 7375 (2015).

  108. 108.

    et al. MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann. Rheum. Dis. 74, 1058–1064 (2015).

  109. 109.

    et al. Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2, e117 (2015).

  110. 110.

    , , , & First-in-patient study of Namilumab, an anti-GM-CSF monoclonal antibody, in active rheumatoid arthritis: results of the Priora Phase 1B study. Ann. Rheum. Dis. 74 (Suppl. 2), 733 (2015)

  111. 111.

    et al. Namilumab, an anti-granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody: results of the first study in patients with mild-to-moderate rheumatoid arthritis (RA). Arthritis Rheumatol. 67 (Suppl. 10), abstr. 969 (2015).

  112. 112.

    et al. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 62, 383–391 (2010).

  113. 113.

    et al. The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum. 62, 3161–3172 (2010).

  114. 114.

    et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res. Ther. 7, R784–R795 (2005).

  115. 115.

    & Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 119, 1810–1820 (2012).

  116. 116.

    & Tissue-resident macrophage ontogeny and homeostasis. Immunity 44, 439–449 (2016).

  117. 117.

    et al. Pleiotropic effects of extended blockade of CSF1R signaling in adult mice. J. Leukoc. Biol. 96, 265–274 (2014).

  118. 118.

    et al. Control of macrophage lineage populations by CSF-1 receptor and GM-CSF in homeostasis and inflammation. Immunol. Cell Biol. 90, 429–440 (2012).

  119. 119.

    et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood 116, 3955–3963 (2010).

  120. 120.

    et al. Crosstalk between muscularis macrophages and enteric neurons regulates gastrointestinal motility. Cell 158, 300–313 (2014).

  121. 121.

    et al. The CSF-1 receptor fashions the intestinal stem cell niche. Stem Cell Res. 10, 203–212 (2013).

  122. 122.

    et al. IL-4 directly signals tissue-resident macrophages to proliferate beyond homeostatic levels controlled by CSF-1. J. Exp. Med. 210, 2477–2491 (2013).

  123. 123.

    et al. Distinct bone marrow-derived and tissue-resident macrophage lineages proliferate at key stages during inflammation. Nat. Commun. 4, 1886 (2013).

  124. 124.

    et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 332, 1284–1288 (2011).

  125. 125.

    et al. A quantifiable proliferative burst of tissue macrophages restores homeostatic macrophage populations after acute inflammation. Eur. J. Immunol. 41, 2155–2164 (2011).

  126. 126.

    et al. M-CSF instructs myeloid lineage fate in single haematopoietic stem cells. Nature 497, 239–243 (2013).

  127. 127.

    , , , & Hematopoietic cytokines can instruct lineage choice. Science 325, 217–218 (2009).

  128. 128.

    et al. Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. J. Exp. Med. 208, 1069–1082 (2011).

  129. 129.

    et al. Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat. Genet. 44, 200–205 (2012).

  130. 130.

    et al. CSF1R mutations link POLD and HDLS as a single disease entity. Neurology 80, 1033–1040 (2013).

  131. 131.

    et al. Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia caused by a novel R782G mutation in CSF1R. Sci. Rep. 5, 10042 (2015).

  132. 132.

    et al. Slan-defined subsets of CD16-positive monocytes: impact of granulomatous inflammation and M-CSF receptor mutation. Blood 126, 2601–2610 (2015).

  133. 133.

    et al. Phenotypic characterization of a Csf1r haploinsufficient mouse model of adult-onset leukodystrophy with axonal spheroids and pigmented glia (ALSP). Neurobiol. Dis. 74, 219–228 (2015).

  134. 134.

    & CSF-1 receptor signaling in myeloid cells. Cold Spring Harb. Perspect. Biol. 6, a021857 (2014).

  135. 135.

    et al. Structure and assembly mechanism of the signaling complex mediated by human CSF-1. Structure 23, 1621–1631 (2015).

  136. 136.

    et al. Structural basis for the dual recognition of helical cytokines IL-34 and CSF-1 by CSF-1R. Structure 20, 676–687 (2012).

  137. 137.

    et al. The mechanism of shared but distinct CSF-1R signaling by the non-homologous cytokines IL-34 and CSF-1. Biochim. Biophys. Acta 1824, 938–945 (2012).

  138. 138.

    & Targeting IL-34 in chronic inflammation. Drug Discov. Today 19, 1212–1216 (2014).

  139. 139.

    et al. Receptor-type protein-tyrosine phosphatase ζ is a functional receptor for interleukin-34. J. Biol. Chem. 288, 21972–21986 (2013).

  140. 140.

    et al. Bone- and cartilage-protective effects of a monoclonal antibody against colony-stimulating factor 1 receptor in experimental arthritis. Arthritis Rheumatol. 66, 2989–3000 (2014).

  141. 141.

    & Colony-stimulating factor-1 in immunity and inflammation. Curr. Opin. Immunol. 18, 39–48 (2006).

  142. 142.

    & Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease. Curr. Top. Med. Chem. 9, 599–610 (2009).

  143. 143.

    et al. Role of M-CSF dependent macrophages in colitis is driven by the nature of the inflammatory stimulus. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G770–G777 (2008).

  144. 144.

    et al. Suppression of macrophage functions impairs skeletal muscle regeneration with severe fibrosis. Exp. Cell Res. 314, 3232–3244 (2008).

  145. 145.

    et al. Colony-stimulating factor (CSF) 1 receptor blockade reduces inflammation in human and murine models of rheumatoid arthritis. Arthritis Res. Ther. 18, 75 (2016).

  146. 146.

    et al. Intra-articular administration of an antibody against CSF-1 receptor reduces pain-related behaviors and inflammation in CFA-induced knee arthritis. Neurosci. Lett. 584, 39–44 (2015).

  147. 147.

    et al. 2-(trimethylammonium) ethyl (R)-3-methoxy-3-oxo-2-stearamidopropyl phosphate suppresses osteoclast maturation and bone resorption by targeting macrophage-colony stimulating factor signaling. Mol. Cells 37, 628–635 (2014).

  148. 148.

    et al. Macrophage depletion ameliorates nephritis induced by pathogenic antibodies. J. Autoimmun. 57, 42–52 (2015).

  149. 149.

    et al. Systemic and cardiac depletion of M2 macrophage through CSF-1R signaling inhibition alters cardiac function post myocardial infarction. PLoS ONE 10, e0137515 (2015).

  150. 150.

    et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25, 846–859 (2014).

  151. 151.

    et al. The promotion of breast cancer metastasis caused by inhibition of CSF-1R/CSF-1 signaling is blocked by targeting the G-CSF receptor. Cancer Immunol. Res. 2, 765–776 (2014).

  152. 152.

    , , , & Emerging roles for CSF-1 receptor and its ligands in the nervous system. Trends Neurosci. 39, 378–393 (2016).

  153. 153.

    , , & Regulation of microglial proliferation during chronic neurodegeneration. J. Neurosci. 33, 2481–2493 (2013).

  154. 154.

    et al. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology. Brain 139, 891–907 (2016).

  155. 155.

    et al. Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice. J. Neuroinflammation 12, 139 (2015).

  156. 156.

    et al. Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival. J. Exp. Med. 210, 157–172 (2013).

  157. 157.

    , , , & Absence of colony stimulation factor-1 receptor results in loss of microglia, disrupted brain development and olfactory deficits. PLoS ONE 6, e26317 (2011).

  158. 158.

    et al. Injured sensory neuron-derived CSF1 induces microglial proliferation and DAP12-dependent pain. Nat. Neurosci. 19, 94–101 (2016). This paper provides evidence that CSF1 represents a pivotal link between peripheral nerve injury and the central mechanisms of neuropathic pain by demonstrating that injured sensory neuron-derived CSF1 induces microglial proliferation and DAP12-dependent neuropathic pain.

  159. 159.

    et al. Macrophage-colony stimulating factor derived from injured primary afferent induces proliferation of spinal microglia and neuropathic pain in rats. PLoS ONE 11, e0153375 (2016).

  160. 160.

    et al. Targeting the colony stimulating factor 1 receptor alleviates two forms of Charcot-Marie-Tooth disease in mice. Brain 138, 3193–3205 (2015).

  161. 161.

    , , & Cell-surface and secreted isoforms of CSF-1 exert opposing roles in macrophage-mediated neural damage in Cx32-deficient mice. J. Neurosci. 36, 1890–1901 (2016).

  162. 162.

    , , & The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF. J. Leukoc. Biol. 68, 144–150 (2000). This paper was the first to show that a mAb against CSF1 can suppress inflammatory disease. It demonstrated that therapeutic administration of a mAb against CSF1 suppressed collagen-induced arthritis in the effector phase of disease.

  163. 163.

    et al. Hypoxia enhances the proliferative response of macrophages to CSF-1 and their pro-survival response to TNF. PLoS ONE 7, e45853 (2012).

  164. 164.

    et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat. Immunol. 11, 936–944 (2010).

  165. 165.

    , , , & Among human macrophages polarised to different phenotypes, the M-CSF-oriented cells present the highest pro-inflammatory response to the rheumatoid arthritis-specific immune complexes containing ACPA. Ann. Rheum. Dis. (2016).

  166. 166.

    et al. Fc gamma receptor-TLR cross-talk elicits pro-inflammatory cytokine production by human M2 macrophages. Nat. Commun. 5, 5444 (2014).

  167. 167.

    & Homeostasis in the mononuclear phagocyte system. Trends Immunol. 35, 358–367 (2014).

  168. 168.

    et al. CSF-1 signaling mediates recovery from acute kidney injury. J. Clin. Invest. 122, 4519–4532 (2012).

  169. 169.

    et al. Proximal tubule-derived colony stimulating factor-1 mediates polarization of renal macrophages and dendritic cells, and recovery in acute kidney injury. Kidney Int. 88, 1274–1282 (2015).

  170. 170.

    et al. CSF1 restores innate immunity after liver injury in mice and serum levels indicate outcomes of patients with acute liver failure. Gastroenterology 149, 1896–1909 (2015).

  171. 171.

    et al. Macrophage colony-stimulating factor (CSF1) controls monocyte production and maturation and the steady-state size of the liver in pigs. Am. J. Physiol. Gastrointest. Liver Physiol. 311, G533–G547 (2016).

  172. 172.

    et al. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. J. Clin. Invest. 124, 4266–4280 (2014).

  173. 173.

    et al. Increase in the level of macrophage colony-stimulating factor in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 67, 429–430 (2008).

  174. 174.

    et al. Urinary levels of RANTES and M-CSF are predictors of lupus nephritis flare. Inflamm. Res. 56, 304–310 (2007).

  175. 175.

    et al. Colony-stimulating factor-1: a potential biomarker for lupus nephritis. J. Am. Soc. Nephrol. 26, 379–389 (2015).

  176. 176.

    , , , & Monoclonal antibodies against macrophage colony-stimulating factor diminish the number of circulating intermediate and nonclassical (CD14++CD16+/CD14+CD16++) monocytes in rheumatoid arthritis patient. Blood 119, 5329–5330 (2012).

  177. 177.

    et al. Structure-guided blockade of CSF1R Kinase in tenosynovial giant-cell tumor. N. Engl. J. Med. 373, 428–437 (2015).

  178. 178.

    et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an ivy foundation early phase clinical trials consortium phase II study. Neuro Oncol. 18, 557–564 (2016).

  179. 179.

    , , , & G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 554–559 (2009).

  180. 180.

    , , & Granulocyte colony-stimulating factor and neutrophils — forgotten mediators of inflammatory disease. Nat. Clin. Pract. Rheumatol. 2, 500–510 (2006).

  181. 181.

    , & The multifactorial role of neutrophils in rheumatoid arthritis. Nat. Rev. Rheumatol. 10, 593–601 (2014).

  182. 182.

    et al. Inhibition of neutrophil apoptosis and modulation of the inflammatory response by granulocyte colony-stimulating factor in healthy and ethanol-treated human volunteers. J. Infect. Dis. 178, 891–895 (1998).

  183. 183.

    et al. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity 22, 285–294 (2005).

  184. 184.

    Anti-inflammatory effects of granulocyte colony-stimulating factor. Curr. Opin. Hematol. 5, 221–225 (1998).

  185. 185.

    et al. Transcription factor, promoter, and enhancer utilization in human myeloid cells. J. Leukoc. Biol. 97, 985–995 (2015).

  186. 186.

    , & Systems approach to phagocyte production and activation: neutrophils and monocytes. Adv. Exp. Med. Biol. 844, 99–113 (2014).

  187. 187.

    G-CSF: a key regulator of neutrophil production, but that's not all! Growth Factors 23, 33–41 (2005).

  188. 188.

    & Felty's syndrome treated with rhG-CSF associated with flare of arthritis and skin rash. Clin. Rheumatol. 14, 204–208 (1995).

  189. 189.

    , & Flare of arthritis with successful treatment of Felty's syndrome with granulocyte colony stimulating factor (GCSF). Clin. Rheumatol. 14, 211–212 (1995).

  190. 190.

    et al. Critical role for granulocyte colony-stimulating factor in inflammatory arthritis. Proc. Natl Acad. Sci. USA 101, 11398–11403 (2004). This was the first report showing that endogenous G-CSF could drive inflammatory disease (arthritis), as G-CSF-deficient mice and mice treated with an anti-G-CSF mAb had reduced arthritis in two mouse models.

  191. 191.

    et al. A key role for G-CSF-induced neutrophil production and trafficking during inflammatory arthritis. Blood 112, 5193–5201 (2008).

  192. 192.

    , , & Granulocyte colony-stimulating factor (G-CSF) plays an important role in immune complex-mediated arthritis. Eur. J. Immunol. 46, 1235–1245 (2016).

  193. 193.

    , & The role of neutrophils and G-CSF in DNFB-induced contact hypersensitivity in mice. Immun. Inflamm. Dis. 2, 21–34 (2014).

  194. 194.

    et al. Neutrophil-related factors as biomarkers in EAE and MS. J. Exp. Med. 212, 23–35 (2015).

  195. 195.

    et al. G-CSF and neutrophils are nonredundant mediators of murine experimental autoimmune uveoretinitis. Am. J. Pathol. 186, 172–184 (2016).

  196. 196.

    et al. NADPH oxidase controls neutrophilic response to sterile inflammation in mice by regulating the IL-1α/G-CSF axis. Blood 126, 2724–2733 (2015).

  197. 197.

    , , & Neutrophils: important contributors to tumor progression and metastasis. Cancer Metastasis Rev. 34, 735–751 (2015).

  198. 198.

    et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522, 345–348 (2015).

  199. 199.

    et al. Neutrophil functions in morbidly obese subjects. Clin. Exp. Immunol. 181, 156–163 (2015).

  200. 200.

    et al. Association of obesity with leukocyte count in obese individuals without metabolic syndrome. Diabetes Metab. Syndr. 8, 197–204 (2014).

  201. 201.

    et al. Administration of granulocyte-colony stimulating factor accompanied with a balanced diet improves cardiac function alterations induced by high fat diet in mice. BMC Cardiovasc. Disord. 15, 162 (2015).

  202. 202.

    et al. Regulation of T helper type-1 immunity in hapten-induced colitis by host pretreatment with granulocyte colony-stimulating factor. Cytokine 23, 23–30 (2003).

  203. 203.

    et al. Recombinant human granulocyte colony-stimulating factor reduces colonic epithelial cell apoptosis and ameliorates murine dextran sulfate sodium-induced colitis. Scand. J. Gastroenterol. 43, 689–697 (2008).

  204. 204.

    et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 84, 1737–1746 (1994).

  205. 205.

    et al. “Emergency” granulopoiesis in G-CSF-deficient mice in response to Candida albicans infection. Blood 95, 3725–3733 (2000).

  206. 206.

    , , & Evaluation of role of G-CSF in the production, survival, and release of neutrophils from bone marrow into circulation. Blood 100, 854–861 (2002).

  207. 207.

    et al. Mice lacking three myeloid colony-stimulating factors (G-CSF, GM-CSF, and M-CSF) still produce macrophages and granulocytes and mount an inflammatory response in a sterile model of peritonitis. J. Immunol. 178, 6435–6443 (2007).

  208. 208.

    et al. Steady-state neutrophil homeostasis is dependent on TLR4/TRIF signaling. Blood 121, 723–733 (2013).

  209. 209.

    et al. Therapeutic targeting of the G-CSF receptor reduces neutrophil trafficking and joint inflammation in antibody-mediated inflammatory arthritis. J. Immunol. 197, 4392–4402 (2016).

  210. 210.

    , , & Protective role of G-CSF in dextran sulfate sodium-induced acute colitis through generating gut-homing macrophages. Cytokine 78, 69–78 (2016).

  211. 211.

    et al. An open-label pilot study of granulocyte colony-stimulating factor for the treatment of severe endoscopic postoperative recurrence in Crohn's disease. Digestion 68, 63–70 (2003).

  212. 212.

    et al. The granulocyte-colony stimulating factor has a dual role in neuronal and vascular plasticity. Front. Cell Dev. Biol. 3, 48 (2015).

  213. 213.

    , & Hematopoietic colony-stimulating factors: new players in tumor-nerve interactions. J. Mol. Med. (Berl.) 89, 321–329 (2011).

  214. 214.

    et al. Granulocyte-colony stimulating factor (G-CSF) induces mechanical hyperalgesia via spinal activation of MAP kinases and PI3K in mice. Pharmacol. Biochem. Behav. 98, 188–195 (2011).

  215. 215.

    et al. Granulocyte-colony stimulating factor (G-CSF)-induced mechanical hyperalgesia in mice: role for peripheral TNFα, IL-1β and IL-10. Eur. J. Pharmacol. 749, 62–72 (2015).

  216. 216.

    , , , & Exogenous granulocyte colony-stimulating factor exacerbate pain-related behaviors after peripheral nerve injury. J. Neuroimmunol. 232, 83–93 (2011).

  217. 217.

    et al. Early systemic granulocyte-colony stimulating factor treatment attenuates neuropathic pain after peripheral nerve injury. PLoS ONE 7, e43680 (2012).

  218. 218.

    et al. Intravenous administration of granulocyte colony-stimulating factor for treating neuropathic pain associated with compression myelopathy: a phase I and IIa clinical trial. Eur. Spine J. 22, 197–204 (2013).

  219. 219.

    et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J. Clin. Invest. 115, 2083–2098 (2005).

  220. 220.

    , & Seeing old friends from a different angle: novel properties of hematopoietic growth factors in the healthy and diseased brain. Hippocampus 22, 1051–1057 (2012).

  221. 221.

    et al. Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody. Cell Rep. 8, 410–419 (2014).

  222. 222.

    et al. Crystal structure of the mouse interleukin-3 β-receptor: insights into interleukin-3 binding and receptor activation. Biochem. J. 463, 393–403 (2014).

  223. 223.

    & Two distinct functional high affinity receptors for mouse interleukin-3 (IL-3). EMBO J. 11, 1875–1884 (1992).

  224. 224.

    Interleukin-3 and hematopoiesis. Chem. Immunol. 51, 65–106 (1992).

  225. 225.

    et al. Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites. Nature 392, 90–93 (1998).

  226. 226.

    et al. Cutting edge: basophils are transiently recruited into the draining lymph nodes during helminth infection via IL-3, but infection-induced Th2 immunity can develop without basophil lymph node recruitment or IL-3. J. Immunol. 184, 1143–1147 (2010).

  227. 227.

    et al. The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling. Immunol. Rev. 250, 277–302 (2012).

  228. 228.

    et al. IL-3 maintains activation of the p90S6K/RPS6 pathway and increases translation in human eosinophils. J. Immunol. 195, 2529–2539 (2015).

  229. 229.

    et al. The interleukin 3 gene (IL3) contributes to human brain volume variation by regulating proliferation and survival of neural progenitors. PLoS ONE 7, e50375 (2012).

  230. 230.

    et al. Signalling by the βc family of cytokines. Cytokine Growth Factor Rev. 24, 189–201 (2013).

  231. 231.

    et al. A novel role for IL-3: human monocytes cultured in the presence of IL-3 and IL-4 differentiate into dendritic cells that produce less IL-12 and shift Th cell responses toward a Th2 cytokine pattern. J. Immunol. 168, 6199–6207 (2002).

  232. 232.

    et al. Recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor show common biological effects and binding characteristics on human monocytes. Blood 74, 2349–2359 (1989).

  233. 233.

    , , & Regulation by interleukin-3 of human monocyte pro-inflammatory mediators. Similarities with granulocyte-macrophage colony-stimulating factor. Immunology 71, 76–82 (1990).

  234. 234.

    , , , & CD123, the plasmacytoid dendritic cell phenotypic marker, is abundant in leprosy type 1 reaction. Br. J. Dermatol. 172, 268–271 (2015).

  235. 235.

    et al. Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis. J. Exp. Med. 168, 1573–1586 (1988).

  236. 236.

    et al. Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proc. Natl Acad. Sci. USA 94, 2150–2155 (1997).

  237. 237.

    et al. Circulating levels of interleukin 10 and other cytokines in rheumatoid arthritis treated with cyclosporin A or combination therapy. J. Rheumatol. 25, 1874–1879 (1998).

  238. 238.

    et al. Association between a single-nucleotide polymorphism in the promoter of the human interleukin-3 gene and rheumatoid arthritis in Japanese patients, and maximum-likelihood estimation of combinatorial effect that two genetic loci have on susceptibility to the disease. Am. J. Hum. Genet. 68, 674–685 (2001).

  239. 239.

    , , & Role of novel biomarkers of inflammation in patients with stable coronary heart disease. Angiology 58, 148–155 (2007).

  240. 240.

    et al. Increased IL-3 serum levels in chronic patients with schizophrenia: associated with psychopathology. Psychiatry Res. 229, 225–229 (2015).

  241. 241.

    , , & Tumor necrosis factor is a critical mediator in hapten induced irritant and contact hypersensitivity reactions. J. Exp. Med. 173, 673–679 (1991).

  242. 242.

    et al. Involvement of interleukin-3 in delayed-type hypersensitivity. Blood 91, 778–783 (1998).

  243. 243.

    et al. Important role of interleukin-3 in the early phase of collagen-induced arthritis. Arthritis Rheum. 60, 1352–1361 (2009).

  244. 244.

    et al. IL-3 attenuates collagen-induced arthritis by modulating the development of Foxp3+ regulatory T cells. J. Immunol. 186, 2262–2272 (2011).

  245. 245.

    et al. IL-3 inhibits TNF-α-induced bone resorption and prevents inflammatory arthritis. J. Immunol. 182, 361–370 (2009).

  246. 246.

    et al. IL-3 contributes to development of lupus nephritis in MRL/lpr mice. Kidney Int. 88, 1088–1098 (2015).

  247. 247.

    et al. Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis. Science 347, 1260–1265 (2015).

  248. 248.

    & Innate response activator B cells: origins and functions. Int. Immunol. 27, 537–541 (2015).

  249. 249.

    , , , & Interleukin-3 prevents neuronal death induced by amyloid peptide. BMC Neurosci. 8, 82 (2007).

  250. 250.

    , , , & Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch. Med. Res. 39, 1–16 (2008).

  251. 251.

    et al. The IL-3/IL-5/GM-CSF common receptor plays a pivotal role in the regulation of Th2 immunity and allergic airway inflammation. J. Immunol. 180, 1199–1206 (2008).

  252. 252.

    et al. CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors. MAbs 8, 436–453 (2016).

  253. 253.

    et al. Simultaneous antagonism of interleukin-5, granulocyte-macrophage colony-stimulating factor, and interleukin-3 stimulation of human eosinophils by targetting the common cytokine binding site of their receptors. Blood 94, 1943–1951 (1999).

  254. 254.

    et al. Novel anti-βc receptor antibody targets multiple effector cell populations in human nasal polyps transplanted into immunodeficient transgenic human interleukin-3 (IL-3)/granulocyte-macrophage colony stimulating factor (GM-CSF) knock-in mice. Am. Thorac. Soc. Meet. 31 abstr. A7903 (2016). This recent report highlights the potential for anti-βc receptor therapy in inflammatory disease.

  255. 255.

    et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica 86, 1261–1269 (2001).

  256. 256.

    et al. A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leuk. Lymphoma 56, 1406–1415 (2015).

  257. 257.

    et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia 28, 2213–2221 (2014).

  258. 258.

    et al. First-in man, phase 1 study of CSL362 (anti-IL3Rα / anti-CD123 monoclonal antibody) in patients with CD123+ acute myeloid leukemia (AML) in CR at high risk for early relapse. Blood 124, 120 (2014).

  259. 259.

    et al. A cytotoxic anti-IL-3Rα antibody targets key cells and cytokines implicated in systemic lupus erythematosus. JCI Insight 1, e86131 (2016). This recent paper highlights the potential for anti-IL-3R therapy in inflammatory disease.

  260. 260.

    et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood 124, 385–392 (2014).

  261. 261.

    et al. Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor α-chain and functions as a specific IL-3 receptor antagonist. Blood 87, 83–92 (1996).

  262. 262.

    et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor α chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5, 31–42 (2009).

  263. 263.

    , & Early start and stop of biologics: has the time come? BMC Med. 12, 25 (2014).

  264. 264.

    Coordinate and noncoordinate colony stimulating factor formation by human monocytes. J. Leukoc. Biol. 55, 355–361 (1994).

  265. 265.

    et al. Granulocyte colony-stimulating factor induces neutrophils to secrete macrophage colony-stimulating factor. Cytokine 15, 299–304 (2001).

Download references

Acknowledgements

The authors thank N. Wilson, A. Lopez and F. Dodeller for fruitful discussion and R. Sallay for typing the Review. J.A.H. and A.D.C. were supported in part from grants (1032147, 1085240 and 1080560) and J.A.H. by a Senior Principal Research Fellowship from the National Health and Medical Research Council of Australia.

Author information

Affiliations

  1. University of Melbourne, Department of Medicine at The Royal Melbourne Hospital, Parkville, Victoria 3050, Australia

    • John A. Hamilton
    •  & Andrew D. Cook
  2. GlaxoSmithKline, Medicines Research Centre, Stevenage SG1 2NY, UK.

    • Paul P. Tak

Authors

  1. Search for John A. Hamilton in:

  2. Search for Andrew D. Cook in:

  3. Search for Paul P. Tak in:

Competing interests

The employer of J.A.H. and A.D.C., the University of Melbourne, has licensed technologies in this area to MorphoSys AG. P.P.T. is an employee and shareholder of GlaxoSmithKline (GSK); GSK is evaluating the efficacy and safety of GSK3196165, an investigational anti-GM-CSF antibody, in patients with rheumatoid arthritis and inflammatory hand osteoarthritis.

Corresponding author

Correspondence to John A. Hamilton.

Glossary

Haematopoiesis

The production of blood cells and platelets, which usually occurs in the bone marrow.

Plasmacytoid dendritic cells

(pDCs). A subset of DCs that specializes in the production of type I interferons. These cells promote antiviral immune responses and are implicated in the pathogenesis of autoimmune diseases that are characterized by a type I interferon gene expression signature.

Invariant natural killer T cells

(Also known as type I natural killer T cells). This well-characterized subset of CD1d-dependent cells expresses an invariant T cell receptor α-chain. These cells recognize lipid antigens presented by CD1d and respond rapidly to danger signals and pro-inflammatory cytokines. Once activated, they engage in multiple effector functions.

Dendritic cell

(DC). An antigen-presenting cell that processes antigen material and presents it on its cell surface to T cells as its main function within the immune system. DCs act as messengers between the innate and the adaptive immune systems.

CD103+ dendritic cells

(CD103+ DCs). A subset of the mouse DC population that is distinguished from other DCs by αE integrin expression. They can be found in many, if not all, lymphoid and non-lymphoid organs.

Myasthenia gravis

A rare, chronic autoimmune disease marked by muscle weakness due to a defect in the action of acetylcholine at neuromuscular junctions.

Experimental autoimmune encephalomyelitis

(EAE). An inflammatory, demyelinating disease of the central nervous system that is the most commonly used model for multiple sclerosis. It is also the prototype for T cell-mediated autoimmune diseases.

T helper cells

(TH cells). A type of T cell that has an important role in the immune system. They help other immune cells by releasing T cell cytokines, thereby helping to regulate immune responses. They are essential for B cell antibody class switching, the activation and growth of cytotoxic T cells and maximizing the bactericidal activity of phagocytes, such as macrophages.

FOXP3+ regulatory T cells

The transcription factor forkhead box P3 (FOXP3) serves as a lineage-specific factor of regulatory T cells, which play a central part in the negative regulation of the immune response to numerous antigens.

CD11c+MHCII+ macrophages

A population of macrophages that is usually present at sites of tissue inflammation. These cells are often called monocyte-derived dendritic cells.

Macrophage polarization

Macrophages respond to diverse microenvironmental signals that trigger different responses, thus resulting in differential polarization patterns into a spectrum of phenotypes from M1 to M2. They are classically activated towards the M1 phenotype by microbial products or interferon-γ and can thereby eradicate invading organisms and promote type I immune responses. Alternative activation by stimulation with interleukin-4 (IL-4), IL-13 or IL-10 drives macrophages towards the M2 phenotype, which is characterized by hyporesponsiveness to pro-inflammatory stimuli and involvement in processes such as debris scavenging, angiogenesis, tissue remodelling, wound healing and the promotion of type II immunity.

Pulmonary alveolar proteinosis

(PAP). A rare lung disease in which an abnormal accumulation of pulmonary surfactant occurs, thereby interfering with gas exchange.

Mononuclear phagocyte system

(MPS). Part of the immune system that consists of the phagocytic cells located in reticular connective tissue. It comprises monocytes, macrophages and dendritic cells and was formerly termed the reticuloendothelial system.

LY6C blood monocytes

A subset of mouse blood monocytes that is generally believed to be the most mature subset and contributes to the immune system through its scavenging and patrolling functions. The analogous population in humans is CD16+ monocytes.

CD16+ monocytes

The most mature subset of human blood monocytes. This population is analogous to LY6C monocytes in mice.

Csf1op/Csf1op mice

These mice have an inactive colony-stimulating factor 1 (Csf1) gene, which results in a developmental defect in several macrophage lineage populations, including osteoclasts. They have an osteopetrotic (op) phenotype.

3xTg-AD mice

Triple-transgenic mice, harbouring presenilin 1 (PSEN1; also known as PS1), amyloid-β precursor protein (APP) and microtubule-associated protein tau (MAPT) transgenes. They progressively develop amyloid-β deposition and neurofibrillary tangles as in Alzheimer disease.

Neutropenia

The presence of abnormally few neutrophils in the blood, which leads to an increased susceptibility to infection.

Hyperalgesia

An increased sensitivity to pain.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrd.2016.231

Further reading